AVE REVENUES DOUBLE IN SECOND QUARTER TO $38 MIL. AS FIRM LOGS $3 MIL. IN U.S. STENT SALES FOLLOWING DEC. 23 APPROVAL; J&J FOURTH QUARTER SALES UP 2.3%
This article was originally published in The Gray Sheet
Executive SummaryArterial Vascular Engineering's $2.9 mil. in initial U.S. sales of the Micro Stent II coronary stent just one week after FDA approval Dec. 23, coupled with strong international stent volume, was the driving force behind a 110% jump in corporate revenues to $38.3 mil. for the second quarter ended Dec. 31.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.